Press Releases Bone Biologics Corporation

Equities

BBLG

US0980705018

Market Closed - Nasdaq Other stock markets 01:30:00 17/05/2024 am IST			5-day change	1st Jan Change
2.2 ^USD	-3.08%		+21.55%	-51.33%

04/05	Certain Common Stock of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	CI
04/05	Certain Warrants of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bone Biologics Announces Closing of $2.0 Million Public Offering	07/03	BU
Bone Biologics Announces Pricing of $2.0 Million Public Offering	04/03	BU
Bone Biologics Reports Progress With NB1 Clinical Program	01/03	BU
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors	11/01	BU
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements	10/01	BU
Bone Biologics Announces 1-for-8 Reverse Stock Split	18/12	BU
Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	20/11	BU
Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	17/11	BU
Nano-Cap Medical Technology Watchlist (ORHB, BBLG, ICU, RMTI)	02/23/02	AQ
Bone Biologics Provides Scientific Update on NB1 Bone Graft Device	26/23/26	BU
Bone Biologics : Submission of Matters to a Vote of Security Holders - Form 8-K	13/23/13	PU
Bone Biologics Prices $5.0 Million Underwritten Public Offering	15/23/15	BU
Bone Biologics Effects 1-for-30 Reverse Stock Split	06/23/06	BU
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia	11/23/11	BU
BONE BIOLOGICS CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	31/23/31	AQ
Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization	26/23/26	BU
BONE BIOLOGICS CORP : Change in Directors or Principal Officers (form 8-K)	22/22/22	AQ
BONE BIOLOGICS CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	22/22/22	AQ
BONE BIOLOGICS CORP Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	14/22/14	AQ
BONE BIOLOGICS CORP : Other Events, Financial Statements and Exhibits (form 8-K)	25/22/25	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Bone Biologics Corporation

Equities

BBLG

US0980705018

Press Releases

Filters